MAX Chat
GlaxoSmithKline Pharmaceuticals Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
2/10
|
56.38 | 50.18 | 12.36% | 45.75 | +23.22% |
| P/S |
|
9.63 | 5.05 | 90.82% |
|
|
| P/BV |
|
18.71 | 6.48 | 188.7% |
|
|
| P/FCF |
|
42.82 | 170.4 | -74.87% |
|
|
| Ev/Ebitda |
|
24.13 | 13.05 | 84.9% |
|
|
| Ev/S |
|
6.31 | 4.85 | 30.27% |
|
|
| Ev/FCF |
|
39.6 | 162.67 | -75.66% |
|
|
| E/P |
|
0.025 | 0.0411 | -39.21% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
8/10
|
26.17 | 19.49 | 34.27% | 22.38 | +16.93% |
| ROE |
|
33.53 | 17.44 | 92.31% |
|
|
| ROA |
|
17.14 | 10.55 | 62.46% |
|
|
| ROIC |
|
0 | 16.48 | -100% |
|
|
| ROS |
|
17.08 | 12.95 | 31.89% |
|
|
| ROCE |
|
0 | 4.27 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0.0172 | 1.04 | -98.34% | 0.013 | +32.19% |
| Nеt Debt/Ebitda |
|
0 | 0.9496 | -100% |
|
|
| Debt/Ratio |
|
0.0044 | 0.1398 | -96.88% |
|
|
| Debt/Equity |
|
1 | 0.9278 | 7.86% |
|
|
| Debt/Net Income |
|
0.0263 | 6.56 | -99.6% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
3.33/10
|
1.33 | 1.17 | 14% | 2.68 | -50.29% |
| Number of years of dividend growth |
|
1 | 0.9692 | 3.17% | ||
| DSI |
|
0.8571 | 0.8355 | 2.59% |
|
|
| Average dividend growth |
|
-2424.34 | -99.78 | 2329.62% |
|
|
| Average percentage for 5 years |
|
2.68 | 1.42 | 87.96% |
|
|
| Average percentage for payments |
|
141.07 | 105.43 | 33.81% |
|
|
| Difference from average difference in sector |
|
0.1633 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
3/10
|
17.2 | 76.03 | -77.38% | ||
| Growth impulse Ebitda in 5 years |
|
23.53 | 43.18 | -45.51% | ||
| Growth impulse Net Income in 5 years |
|
158.99 | 147.83 | 7.55% | ||
| Growth impulse FCF in 5 years |
|
137.06 | 94.68 | 44.76% | ||
| Growth impulse EPS in 5 years |
|
159 | 113.18 | 40.48% |
IP Score
5.99/10
